Understanding the impact of the patients’ sex on clinical outcomes to treatment with immunotherapy might add another piece to the puzzle of the most effective way to use checkpoint inhibitors.

Encouraging early data suggests PD-1 blockade is also effective in other advanced non-melanoma skin cancers such as advanced basal cell carcinoma.

Studies presented at the ESMO Virtual Congress 2020 report high expenditure in the research and development process and discrepancies in costs of therapies among countries

A new treatment paradigm for men with metastatic castration-resistant prostate cancer (mCRPC) and BRCA1, BRCA2 or ATM mutations

Some studies presented at the ESMO Virtual Congress 2020 also show promise in addressing unmet needs in NETs, while a survey reveals delays in diagnosis or misdiagnosis are still common

Updates from three large global registries confirm that cancer is an independent adverse factor in people infected with coronavirus

The LungART trial provides conclusive evidence that mediastinal post-operative radiotherapy should not be used routinely in these patients, and that radical surgery can remain a single local modality, to be followed by a watch-and-wait strategy 

Innovations focussing on the macrophage compartment with MK-4830 and on T-cell co-stimulation with PRS-343 demonstrate the continued benefits of translational research in oncology

First results from the LEAP-005 study show pretreated advanced cancers respond to the combination treatment

Data presented at ESMO Virtual Congress 2020 reported on safety profiles of some MET inhibitors when combined with tyrosine kinase inhibitors and encouraging response rates in patients with non-small-cell lung cancer with MET exon 14 skipping mutations